← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-10 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleRochePhase 2

trastuzumab (Herceptin, pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy)

HER2-positive Breast Cancer; Neoadjuvant Therapy · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleJiangsu Hengrui Pharmaceutical …Phase 2

trastuzumab (Herceptin, pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 2

radiochemotherapy,combination Cetuximab-FOLFOX (radiochemotherapy,combination Cetuximab-FOLFOX)

Esophageal Cancer Stage III · Esophageal Cancer Stage III

#EsophagealCancerStageIII#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

recombinant human thrombopoietin (rhTPO, recombinant human thrombopoietin, recombinant human thrombopoietin (rhTPO); rituximab)

Purpura; Idiopathic Thrombocytopenic Purpura · Purpura

#Purpura#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleThe Affiliated Hospital of Qing…Phase 1

HS627 (recombinant monoclonal antibody against human epidermal growth factor receptor injection, recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627))

Healthy Volunteers · Healthy Volunteers

#HealthyVolunteers#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleDan LiangPhase 2

adalimumab (Humira, reduction or discontinuation of Adalimumab)

Uveitis; Adalimumab · Uveitis

#Uveitis#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleUniversity of UtahPhase 1

regorafenib + panitumumab (regorafenib + panitumumab)

KRAS and NRAS Wild-type Colorectal Cancer · KRAS and NRAS Wild-type Colorectal Cance

#KRASandNRASWild-typeColorectalCa#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, relatlimab+nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 44.4%임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, relatlimab+nivolumab+rHuPH20)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPreclinical

response to infliximab associated with methotrexate (response to infliximab associated with methotrexate)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleGenentech, Inc.Phase 3

ranibizumab (rhuFab V2, rhuFab V2 (ranibizumab))

Macular Degeneration · Macular Degeneration

#MacularDegeneration#Antibody#Phase3#항체#면역항체+2
효능 ORR 56.4%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Bevacizumab (rhuMAb VEGF, rhuMAb VEGF (Bevacizumab))

Renal Cell Cancer · Renal Cell Cancer

#RenalCellCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

rituximab /Dexamethasone/cyclophosphamide (rituximab /Dexamethasone/cyclophosphamide)

Treatment · Treatment

#Treatment#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRocheApproved

rituximab and everolimus (rituximab and everolimus)

Renal Insufficiency · Renal Insufficiency

#RenalInsufficiency#Antibody#Approved#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRocheApproved

rituximab combined with corticosteroids (rituximab combined with corticosteroids)

Primary Membranous Nephropathy · Primary Membranous Nephropathy

#PrimaryMembranousNephropathy#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim (rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim)

Hodgkin's Disease; Lymphoma · Hodgkin's Disease

#HodgkinsDisease#Antibody#Phase2#항체#면역항체+3
효능 ORR 32%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone (rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin (rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim (rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim)

Large B Cell Lymphoma · Large B Cell Lymphoma

#LargeBCellLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

rituximab, ifosfamide, carboplatin, and etoposide phosphate (rituximab, ifosfamide, carboplatin, and etoposide phosphate)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING

90 / 92 페이지

← 이전다음 →